Arnold, Guy: Früh- und Differentialdiagnose von Parkinson-Syndromen unter besonderer Berücksichtigung des Steele-Richardson-Olszewski-Syndroms

100

Literatur

M, Hosoya T, Haku T, Yamaguchi K, Kawanami T. "Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted MR imaging. " AJNR Am J Neuroradiol 1999; 20: 1500-1506

Aiba I, Hashizume Y, Yoshida M, Okuda S, Murakami N, Ujihira N. "Relationship between brainstem MRI and pathological findings in progressive supranuclear palsy--study in autopsy cases. " J Neurol Sci 1997; 152: 210-217

Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. "T2 relaxation time in patients with Parkinson's disease. " Neurology 1993; 43: 697-700

Arnold G, Schwarz J, Macher C, Oertel WH. "Domperidone is superior to Ondansetron in acute apomorphine challenge in previously untreated parkinsonian patients - a double blind study. " Parkinsonism and Related Disorders 1998; 3: 191-193

Arnold G, Schwarz J, Tatsch K, Kraft E, Bandmann O, Oertel WH. "Steele-Richardson-Olszewski-Syndrome: The relation of dopamine D2 receptor binding and subcortical lesions in MRI. " J Neural Transm (eingereicht)

Arnold G, Tatsch K, Kraft E, Oertel WH, Schwarz J. "Steele-Richardson-Olszewski-Syndrome:The reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: a 123IBZM SPECT and MRI study. " Mov Dis (eingereicht)

Arnold G, Tatsch K, Oertel WH, Vogl Th, Schwarz J, Kraft E, Kirsch CM. "Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. " J Neural Transm [Suppl.] 1994, 42: 111-118

Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D. "Parkinson's disease and parkinsonism in a longitudinal study: Two-fold higher incidence in men. " Neurology 2000; 55: 1358-1363

Baron JC, Mazière B, Loc'h C, Cambon H, Sgouropoulos P, Bonnet AM, Agid Y. "Loss of striatal [76-Br]bromospiperone binding sites demonstrated by positron emission tomography in progressive supranuclear palsy. " J Cereb Blood Flow Metab 1985; 6: 131-136

Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J. "MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. " Magn Reson Imaging 1999; 17: 213-222

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. "Brain dopamine and the syndromes of Parkinson and Huntington. " J Neurol Sciences 1973; 20: 415-455

Binswanger O. "Die Abgrenzung der allgemeinen progressiven Paralyse, I-III. " Berl Klin WochenschR 1894; 49: 1103-1105, 1137-1139, 1180-1186

Birkmayer WO, Hornykiewicz O. "Der L-Dioxyphenylalanin (= L-Dopa)-Effekt bei der Parkinson-Akinese. " Wien Klein WschR 1961; 73: 787-788

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA. "[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. " J Neurol Neurosurg Psychiatry 1997; 62: 133-140

Brooks DJ, Ibanez V, Sawle GV, Quin N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RSJ. "Differing patterns of striatal 18F-dopa uptake in Parkinson‘s disease, multiple system atrophy, and progressive supranuclear palsy. " Ann Neurol 1990, 28: 547-555


101

Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS. "Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. " Ann Neurol 1992; 31: 184-192

Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B, Muller C, Deecke L. "Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. " J Cereb Blood Flow Metab 1991; 11: 220-228

Brücke T, Wenger S, Asenbaum S, Fertl, E, Pfafflmeyer, N, Müller Ch, Podreka I, Angelberger P. "Dopamine D2 receptor imaging and measuring with SPECT. " In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds.) Advances in Neurology, Vol. 60 (Parkinson‘s Disease. From basic research to therapy). Raven Press, New York 1993; 494-500

Burn DJ, Sawle GV, Brooks DJ. "Differential diagnosis of Parkinson‘s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. " J Neurol Neurosurg Psychiatry 1994, 57: 278-284

Carlsson A, Lindquist M, Magnusson T. "3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. " Nature 1957; 180: 1200.

Collins SJ, Ahlskog JE, Parisi JE, Maraganore DM. "Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. " J Neurol Neurosurg Psychiatry 1995; 58: 167-173

Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. "Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. " J Neurol Neurosurg Psychiatry 1996; 60: 634-637

Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen X, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R, Xia Y, Saitoh T. "Genetic evidence for the involvement of tau in progressive supranuclear palsy. " Ann Neurol 1997; 41: 277-281

Critchly M. "Arteriosclerotic Parkinsonism. " Brain 1929; 52: 23-83

Davie CA, Barker GJ, Machado C, Miller DH, Lees AJ. "Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. " Mov Disord 1997; 12: 767-771

Davis PH, Golbe LI, Duvoisin RC, Schoenberg BS. "Risk factors for progressive supranuclear palsy. " Neurology 1988; 38: 1546-1552

De Bruin VMS, Lees AJ, Daniel SE. "Diffuse Lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: a case report. " Mov Dis 1992; 7: 355-358

De Bruin VMS, Lees AJ. "Subcortical neurofibrillary degeneration presenting as Steele-Richardson-Olszewski and other related syndromes: A review of 90 pathologically verified cases. " Mov Disord 1994, 9: 381-389

Doraiswamy PM, Na C, Husain MM, Figiel GS, McDonald WM, Ellinwood EH, Boyko OB, Krishnan KRR. "Morphometric changes of the human midbrain with normal aging: MR and stereologic findings. " AJNR 1992; 13: 383-386

Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer S. "Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. " Radiology 1986; 159: 493-498

Dubinsky RM, Jankovic J. "Progressive supranuclear palsy and a multi infarct state. " Neurology 1987; 37: 570-576


102

Eriksson L, Larsson S, Bergstrand G, Roland P. "Regional cerebral blood flow determined with single photon emission computed tomography and positron emission tomography. A comparative study. " Acta Radiol Suppl. 1986; 369: 453-455

Fahn S, Elton RL, and Members of the UPDRS Development Committee. "Unified Parkinson‘s Disease Rating Scale. " In: Fahn S, Marsden CD, Goldstein M (eds.) Recent development in Parkinson‘s Disease II. New York, Macmillan 1987; 153-163.

Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, Litton JE, Sedvall G. "Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. " Proc Natl Acad Sci USA 1985; 82: 3863-3867

Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H. "Pathologic correlates of incidental MRI white matter signal hyperintensities. " Neurology 1993; 43: 1683-1689

Fenelon G, Houeto JL. "Les syndromes parkinsoniens vasculaires: un concept controverse. " Rev Neurol (Paris) 1998; 154: 291-302

Firnau G, Garnett ES, Chirakal R, Sood S, Nahmias C, Schrobilgen G. "[18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine. " Int J Rad Appl Instrum [A] 1986; 37: 669-675

Foster NL, Gilman S, Berent S, Sima AAF, D‘Amato C, Koeppe RA, Hicks SP. "Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. " J Neurol Neurosurg Psychiatry 1992; 55: 707-713

Frankel JP, Lees AJ, Kempster PA, Stern GM. "Subcutaneous apomorphine in the treatment of Parkinson's disease. " J Neurol Neurosurg Psychiatry 1990; 53: 96-101

Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann RD. "A susceptibility locus for Parkinson's disease maps to chromosome 2p13. " Nat-Genet. 1998; 18: 262-265

Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. "Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. " Arch Neurol 1992; 49: 1131-1134

Gearing M, Olson DA, Watts RL, Mirra SS. "Progressive supranuclear palsy: neuropathologic and clinical heterogeneity. " Neurology 1994; 44: 1015-1024

George MS, Robertson MM, Costa DC, Ell PJ, Trimble M, Pilowsky L, Verhoeff NP. "Dopamine receptor availability in Tourette's syndrome. " Psychiatry-Res. 1994; 55: 193-203

Ghorayeb I, Fernagut PO, Aubert I, Bezard E, Poewe W, Wenning GK, Tison F. "Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. " Mov Disord 2000; 15: 531-536

Gibb WR, Lees AJ. "The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. " Neuropathol-Appl-Neurobiol. 1989; 15: 27-44

Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK. "Consensus statement on the diagnosis of multiple system atrophy. " J Neurol Sci 1999; 163: 94-98

Golbe LI, Davis PH, Schoenberg BS, Duvoisin RC. "Prevalence and natural history of progressive supranuclear palsy. " Neurology 1988; 38: 1031-1034


103

Hakim S, Adams RD. "The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. " J-Neurol-Sci. 1965; 2: 307-327

Haldeman S, Goldman JW, Hyde J, Pribram HFW. "Progressive supranuclear palsy, computed tomography, and response to antiparkinsonian drugs. " Neurology 1981, 31: 442-445

Harasko van der Meer C, Brucke T, Wenger S, Fischer P, Deecke L, Podreka I. "Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. " J Neural Transm Gen Sect 1993; 94: 217-221

Hauser RA, Olanow CW. "Magnetic resonance imaging of neurodegenerative diseases. " J Neuroimaging 1994; 4: 146-158

Hierholzer J, Cordes M, Venz S, Schelosky L, Harisch C, Richter W, Keske U, Hosten N, Maurer J, Poewe W, Felix R. "Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. " J Nucl Med. 1998; 39: 954-960

Hierholzer J, Schrag A, Cordes M, Sander B, Schelosky L, Harisch C, Venz S, Keske U, Maurer J, Poewe W, Felix R. "[Magnetic resonance tomography in patients with Parkinson's disease and Parkinson-plus syndromes]. " Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 1996; 165: 43-51

Huber SJ, Chakeres DW, Paulson GW, Khanna R. "Magnetic resonance imaging in Parkinson's disease. " Arch Neurol. 1990; 47: 735-737

Hughes AJ, Lees AJ, Stern GM. "Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. " Neurology 1991; 41: 1723-1725

Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, et al. "Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. " Proc Natl Acad Sci USA 1993; 90: 11965-11969

Ito K, Morrish PK, Rakshi JS, Uema T, Ashburner J, Bailey DL, Friston KJ, Brooks DJ. "Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease. " J Neurol Neurosurg Psychiatry 1999; 66: 754-758

Jankovic J, Friedmann DI, Pirozzolo FJ, McCrary JA. "Progressive supranuclear palsy: Motor, neurobehavioral, and neuro-ophthalmic findings. " In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH (eds.) Advances in Neurology, Vol. 53 (Parkinson's Disease. Anatomy, Pathology, and Therapy). Raven Press, New York, 1990; 293-304

Jellinger K. "Pathology of parkinsonism. " In: S. Fahn, C.D. Marsden and R. Duvoisin (eds.) Recent Developments in Parkinsonism. Raven Press, New York, 1986; 33-66

Jenner P. "Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. " Ann Neurol 2000; 47: 90-99

Katzman R, Hussey F. "A simple constant-infusion manometric test for measurement of CSF absorption. I. Rationale and method. " Neurology 1970; 20: 534-544

Ketonen LM. "Neuroimaging of the aging brain. " Neurol Clin 1998; 16: 581-598

Kida E, Barcikowska M, Niemczewska M. "Immunohistochemical study of a case with progressive supranuclear palsy without ophthalmoplegia. " Acta Neuropathol (Berl) 1992; 83: 328-332

Konagaya M, Konagaya Y, Iida M. "Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. " J Neurol Neurosurg Psychiatry 1994; 57: 1528-1531


104

Kung HF, Alavi A, Chang W, Kung M-P, Keyes JW, Velchik MG, Billings J, Pan S, Noto R, Rausch A, Reilley J. "In vivo SPECT imaging of CNS D-2 dopamine receptors: Initial studies with iodine-123-IBZM in humans. " J Nucl Med 1990, 31: 573-579

Kung HF, Guo YZ, Billings J, Xu X, Mach RH, Blau M, Ackerhalt RE. "Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. " Int J Rad Appl Instrum B 1988; 15: 195-201

Langston JW, Ballard P, Tetrud JW, Irwin I. "Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. " Science 1983; 219: 979-980

Langston JW, Forno LS, Rebert CS, Irwin I. "Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. " Brain Res. 1984; 292: 390-394

Lassen NA, Henriksen L, Holm S, Barry DI, Paulson OB, Vorstrup S, Rapin JR, Le Poncin-Lafitte M, Moretti JL, Askienazy S, Raynaud C. "Cerebral blood flow tomography by SPECT (single photon emission computerized tomography): Xenon-133 compared to isopropyl-amphetamine-iodine-123. " Ann Radiol (Paris) 1983; 26: 53-58

Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD. "Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. " J Neurol Neurosurg Psychiatry 1986; 49: 853-860

Lees AJ. "The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). " In: Marsden CD, Fahn S (eds.) Movement Disorders 2, Butterworth, London 1987; 272-287

Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. "Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. " Nat Genet 2000; 25: 402-405

Lewy FM. "Zur pathologischen Anatomie der Paralysis agitans. " Dtsch Z Nervenheilk 1913; 50: 50-55

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. "Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. " Neurology 1996; 47: 1-9

Litvan I, Agid Y, Goetz C, Jankovic J, Wenning G, Brandel JP, Lai EC, Verny M, Ray-Chaudhuri K, McKee A, Jellinger K, Pearce RKB, Bartko JJ. "Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathological study. " Neurology 1997, 48: 119-125.

Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, Wenning G, D‘Olhaberiague L, Verny M, Ray Chaudhuri K, McKee A, Jellinger K, Bartko JJ, Mangone CA, Pearce RKB. "Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). " Neurology 1996; 46: 922-930

Litvan I, Dickson DW, Buttner-Ennever JA, Delacourte A, Hutton M, Dubois B, Golbe LI, Hallett M, Schellenberg GD, Standaert D, Brooks DJ, Price D. "Research goals in progressive supranuclear palsy. First International Brainstorming Conference on PSP. " Mov Disord 2000; 15: 446-458

Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, McKee A, Jellinger K, Lai EC, Brandel JP, Verny M, Chaudhuri KR, Pearce RK, Agid Y. "What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. " Arch Neurol 1997; 54: 937-944

Litvan I, Lees AJ. "Progressive supranuclear palsy. " Adv Neurol 1999; 80: 341-345

Litvan I, Mangone CA, McKee A, Verny M, Parsa A, Jellinger K, D'Olhaberriague L, Chaudhuri KR, Pearce RK. "Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. " J Neurol Neurosurg Psychiatry 1996; 60: 615-620


105

Lloyd KG. "CNS compensation to dopamine neuron loss in Parkinson's disease. " Adv Exp Med Biol. 1977; 90: 255-266

Maher ER, Lees AJ. "The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). " Neurology 1986; 36: 1005-1008

Malison RT, Vessotskie JM, Kung MP, McElgin W, Romaniello G, Kim HJ, Goodman MM, Kung HF. "Striatal dopamine transporter imaging in nonhuman primates with iodine-123-IPT SPECT. " J Nucl Med 1995; 36: 2290-2297

Matsumine H, Saito M, Shimoda-Matsubayashi S, Tanaka H, Ishikawa A, Nakagawa-Hattori Y, Yokochi M, Kobayashi T, Igarashi S, Takano H, Sanpei K, Koike R, Mori H, Kondo T, Mizutani Y, Schaffer AA, Yamamura Y, Nakamura S, Kuzuhara S, Tsuji S, Mizuno Y. "Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. " Am J Hum Genet 1997; 60: 588-596

Matsuo H, Takashima H, Kishikawa M, Kinoshita I, Mori M, Tsujihata M, Nagataki S. "Pure akinesia: an atypical manifestation of progressive supranuclear palsy. " J Neurol Neurosurg Psychiatry 1991; 54: 397-400

Menegon A, Board PG, Blackburn AC, Mellick GD, Le-Couteur DG. "Parkinson's disease, pesticides, and glutathione transferase polymorphisms. " Lancet 1998; 352: 1344-1346

Messa C, Volonte MA, Fazio F, Zito F, Carpinelli A, d'Amico A, Rizzo G, Moresco RM, Paulesu E, Franceschi M, Lucignani G. "Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. " Eur J Nucl Med 1998; 25: 1270-1276

Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. "Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. " Acta Neurol Scand 1994; 89: 164-170

Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. "Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. " J Neurol Neurosurg Psychiatry 1998; 64: 314-319

Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. "The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport " N Engl J Med 1984; 310: 483-488

Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. "IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome. " Adv Neurol 1993; 60: 519-524

Oliva R, Tolosa E, Ezquerra M, Molinuevo JL, Valldeoriola F, Burguera J, Calopa M, Villa M, Ballesta F. "Significant changes in the tau A0 and A3 alleles in progressive supranuclear palsy and improved genotyping by silver detection. " Arch Neurol 1998; 55: 1122-1124

Parkinson J. An essay on shaking palsy. " " London, 1817

Pastakia B, Polinsky R, Di Chiro G, Simmons JT, Brown R, Wener L. "Multiple system atrophy (Shy-Drager syndrome): MR imaging. " Radiology 1986; 159: 499-502

Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. "Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). " Mov Disord 1995; 10: 731-740


106

Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Agid F, Ruberg M, Agid Y. "D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. " J Neurol Sci 1988; 86: 291-306

Pinter MM, Alesch F, Murg M, Helscher RJ, Binder H. "Apomorphine test: a predictor for motor responsiveness to deep brain stimulation of the subthalamic nucleus. " J Neurol 1999; 246: 907-913

Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. "Subcutaneous apomorphine in Parkinson's disease. " Lancet 1988; 1: 943

Pollock NJ, Mirra SS, Binder LI, Hansen LA, Wood JG. "Filamentous aggregates in Pick's disease, progressive supranuclear palsy, and Alzheimer's disease share antigenic determinants with microtubule-associated protein, tau. " Lancet 1986; 2: 1211

Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Die SE, Di-Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC. "Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. " Science 1996; 274: 1197-1199

Quinn N, Critchley P, Marsden CD. "Young onset Parkinson's disease. " Mov Disord 1987; 2: 73-91

Radau PE, Linke R, Slomka PJ, Tatsch K. "Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. " J Nucl Med. 2000; 41: 220-227

Reichmann H, Janetzky B. "Mitochondrial dysfunction - a pathogenetic factor in Parkinson‘s disease. " J Neurol 2000; 247[Suppl. 2]: II/63-II/68

Rivaud-Pechoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. "Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. " Neurology 2000; 54: 1029-1032

Rossi P, Colosimo C, Moro E, Tonali P, Albanese A. "Acute challenge with apomorphine and levodopa in Parkinsonism. " Eur Neurol 2000; 43: 95-101

Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S. "Study of movement disorders and brain iron by MR. " AJR Am J Roentgenol 1987; 149: 365-379

Sachs L. Angewandte Statistik, " " 9.Auflage, Springer Verlag, Berlin, Heidelberg, 1999

Savoiardo M, Strada L, Girotti F, D'Incerti L, Sberna M, Soliveri P, Balzarini L. "MR imaging in progressive supranuclear palsy and Shy-Drager syndrome. " J Comput Assist Tomogr. 1989; 13: 555-560

Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W. "Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. " Mov Disord. 1993; 8: 453-458

Schonfeld SM, Golbe LI, Sage JI, Safer JN, Duvoisin RC. "Computed tomographic findings in progressive supranuclear palsy: correlation with clinical grade. " Mov Disord 1987; 2: 263-278

Schrag A, Ben-Shlomo Y, Quinn NP. "Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. " Lancet 1999; 354: 1771-1775

Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, Quinn NP. "Differentiation of atypical parkinsonian syndromes with routine MRI. " Neurology 2000; 54: 697-702

Schulz JB, Klockgether T, Petersen D, Jauch M, Muller-Schauenburg W, Spieker S, Voigt K, Dichgans J. "Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. " J Neurol Neurosurg Psychiatry 1994; 57: 1047-1056


107

Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, Voigt K, Dichgans J, Klockgether T. "Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. " Ann Neurol 1999; 45: 65-74

Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. "Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. " Nucl Med Commun 1994; 15: 806-813

Schwarz J, Kraft E, Vogl T, Arnold G, Tatsch K, Oertel WH. "Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism. " Neuroradiology 1999; 41: 124-128

Schwarz J, Oertel WH, Tatsch K. "Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. " J Nucl Med 1996; 37: 1112-1115

Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH. "[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. " Mov Disord 1997; 12: 898-902

Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, Oertel WH. "123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. " Neurology 1993; 43[Suppl. 6]: S17-S20

Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Kunig G, Oertel WH. "123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. " Mov Disord 1998; 13: 16-19

Schwarz J, Tatsch K, Vogl T, Kirsch CM, Trenkwalder C, Arnold G, Gasser T, Oertel WH. "Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia. " Mov Disord 1992; 7: 58-61

Schwarz J, Weis S, Kraft E, Tatsch K, Bandmann O, Mehraein P, Vogl T, Oertel WH. "Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. " J Neurol Neurosurg Psychiatry 1996; 60: 98-101

Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E. "Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. " Neurology 1996; 46: 1275-1278

Sergeant N, Wattez A, Delacourte A. "Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. " J Neurochem 1999 72: 1243-1249.

Spillantini MG, Goedert M. "Tau protein pathology in neurodegenerative diseases. " Trends Neurosci 1998; 21: 428-433

Steele JC, Richardson JC, Olszewski J. "Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. " Arch Neurol 1964; 10: 333-359

Stocchi F, De Pandis MF, Delfino FA, Anselmo T, Frongillo D. "Transient atrial fibrillation after subcutaneous apomorphine bolus. " Mov Disord 1996; 11: 584-585

Tatsch K, Schwarz J, Oertel WH, Kirsch CM. "SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. " Nucl Med Commun 1991; 12: 699-707

Tatsch K, Schwarz J, Mozley PD, Linke R, Pogarell O, Oertel WH, Fieber RS, Hahn K, Kung HF. "Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. " Eur J Nucl Med 1997; 24: 415-421


108

Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, Feldman RG, Myers RH. "Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. " Am J Med Genet 1999; 88: 742-749

Tretiakoff C. Conribution à l‘étude de l‘anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives à la pathologie des troubles musculaires et de la maladie de Parkinson. Jouvre, Paris 1919

Vallabhajosula S, Zimmerman RE, Picard M, Stritzke P, Mena I, Hellman RS, Tikofsky RS, Stabin MG, Morgan RA, Goldsmith SJ. "Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. " J Nucl Med 1989; 30: 599-604

van der Valk R, Jörg J. "Aktuelle Aspekte zur Diagnostik des Morbus Parkinson. " Acta Histochem Suppl 1992; 42: 51-58

van Royen E, Verhoeff NFLG, Speelman JD, Wolters EC, Kuiper MA, Janssen AGM. "Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. " Arch Neurol 1993, 50: 513-516

Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. "Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. " J Nucl Med 1993; 34: 2076-2084

Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. "123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. " Mov Disord 1998; 13: 438-445

Will RG, Lees AJ, Gibb W, Barnard RO. "A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski-Syndrome. " J Neurol Neurosurg Psychiatry 1988, 51: 1224-1227

Yagishita A, Oda M. "Progressive supranuclear palsy: MRI and pathological findings. " Neuroradiology. 1996 May; 38 Suppl 1:S60-66

Yamauchi H, Fukuyama H, Nagahama Y, Katsumi Y, Dong Y, Konishi J, Kimura J. "Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy. " Ann Neurol. 1997; 41: 606-614

Ye FQ, Allen PS, Martin WR. "Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. " Mov Disord 1996; 11: 243-249


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiML DTD Version 2.0
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Tue Oct 2 11:51:58 2001